Otsu K, Guo R, Dreskin S C
Division of Allergy and Clinical Immunology and Departments of Medicine and Immunology, University of Colorado Denver, Aurora, CO, USA.
Clin Exp Allergy. 2015 Feb;45(2):471-84. doi: 10.1111/cea.12407.
Ara h 2 and Ara h 6 are moderately homologous and highly potent peanut allergens.
To identify IgE-binding linear epitopes of Ara h 6, compare them to those of Ara h 2, and to stratify binding based on clinical histories.
Thirty highly peanut-allergic subjects were stratified by clinical history. Sera were diluted to contain the same amount of anti-peanut IgE. IgE binding to overlapping 20-mer peptides of Ara h 2 and Ara h 6 was assessed using microarrays.
Each subject had a unique IgE-binding fingerprint to peptides; these data were coalesced into epitope binding. IgE from subjects with a history of more severe reactions (n = 19) had a smaller frequency of binding events (BEs) for both Ara h 2 (52 BEs of 152 (19X8epitopes) possible BEs and Ara h 6 (13 BEs of 133 (19X7 epitopes) possible BEs) compared to IgE from those with milder histories (n = 11) (Ara h 2: 47 BEs of 88 (11X8 epitopes) possible BEs, P < 0.01; Ara h 6: 25 BEs of 77 (11X7 epitopes) possible BEs, P < 0.001). Using an unsupervised hierarchal cluster analysis, subjects with similar histories tended to cluster. We have tentatively identified a high-risk pattern of binding to peptides of Ara h 2 and Ara h 6, predominantly in subjects with a history of more severe reactions (OR = 12.6; 95% CI: 2.0-79.5; P < 0.01).
IgE from patients with more severe clinical histories recognize fewer linear epitopes of Ara h 2 and Ara h 6 than do subjects with milder reactions and bind these epitopes in characteristic patterns. Close examination of IgE binding to epitopes of Ara h 2 and Ara h 6 may have prognostic value.
Ara h 2和Ara h 6是中度同源且强效的花生过敏原。
鉴定Ara h 6的IgE结合线性表位,将其与Ara h 2的表位进行比较,并根据临床病史对结合情况进行分层。
30名花生高度过敏受试者按临床病史分层。将血清稀释至含有等量的抗花生IgE。使用微阵列评估IgE与Ara h 2和Ara h 6重叠20肽段的结合。
每位受试者对肽段都有独特的IgE结合指纹图谱;这些数据合并为表位结合情况。与病史较轻的受试者(n = 11)相比,有更严重反应病史的受试者(n = 19)的IgE对Ara h 2(152个(19×8个表位)可能的结合事件中有52个结合事件)和Ara h 6(133个(19×7个表位)可能的结合事件中有13个结合事件)的结合事件频率较低(Ara h 2:88个(11×8个表位)可能的结合事件中有47个结合事件,P < 0.01;Ara h 6:77个(11×7个表位)可能的结合事件中有25个结合事件,P < 0.001)。使用无监督层次聚类分析,病史相似的受试者倾向于聚类。我们初步确定了一种与Ara h 2和Ara h 6肽段结合的高风险模式,主要出现在有更严重反应病史的受试者中(比值比 = 12.6;95%置信区间:2.0 - 79.5;P < 0.01)。
与反应较轻的受试者相比,有更严重临床病史的患者的IgE识别出的Ara h 2和Ara h 6线性表位更少,并以特征性模式结合这些表位。仔细检查IgE与Ara h 2和Ara h 6表位的结合情况可能具有预后价值。